22 May 2026VideosAmericasRachel Elsby, Akin Gump | Mark Nickas, Alnylam Pharmaceuticals | Teofilo Javier, Bristol Myers Squibb | Kevin Yurkerwich, Novartis | Nicole Clouse, Generate Biomedicines

WATCH: Overcoming patent eligibility, patentability, and disclosure requirements in life sciences innovation

How can innovators secure reliable protection across diagnostics, genetics, and AI-integrated devices while navigating Section 101 and 112 pitfalls? This comprehensive panel addresses strategies to clear fundamental patentability hurdles amid shifting court decisions and USPTO guidelines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Kirkland clears conflicts hurdle in trade secrets spat

Former senior attorney-advisor to ITC commissioners joins Mintz

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

Patent litigator joins Baker Botts in London as UPC grows in significance

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

WATCH: Overcoming patent eligibility, patentability, and disclosure requirements in life sciences innovation

More on this story

Editor's picks

Editor's picks

More features